- Research Services
- Capabilities
- About Us
- Resources
- Contact Us
At BioModels, assess your novel therapeutic for efficacy and/or mechanism of action in our established cachexia dexamethasone-induced muscle atrophy model to address an unmet clinical need for patients. Cachexia, or wasting syndrome, is a complex, multifactorial metabolic disorder characterized by loss of appetite, fatigue, weight loss, and muscle mass loss. Disease is induced in mice through daily consumption of dexamethasone in the drinking water, as adverse side effects of high dose, continued usage of glucocorticoids has been demonstrated. Animals are assessed daily for body weight change and water consumption. Body composition analysis (DEXA) is evaluated at multiple timepoints during the study. At the conclusion of the study, select muscles are weighed for comparison between treatment groups.
Dexamethasone is administered in the drinking water from Day 0 to Day 14 to induce muscle wasting. Animals are weighed daily, and body weight changes as compared to Day 0 are calculated. The AUC is calculated to compare treatment arms and is shown in the inset.
Dexamethasone is administered in the drinking water from Day 0 to Day 14 to induce muscle wasting. Body composition analysis is performed at various timepoints during the study. Day 14 DEXA analysis is shown including total lean tissue mass (left), total fat mass (middle), and total percent body fat (right). (**p<0.01; ***p<0.001).
Dexamethasone is administered in the drinking water from Day 0 to Day 14 to induce muscle wasting. Muscle weights are determined at the study termination for various muscle groups. (*p<0.05).
